Cornea

Noncontact esthesiometry screens for all levels of neurotrophic keratitis.

The study of pathological tissues will enable to establish the role of corneal structure in certain diseases.

The trial will be conducted by French tissue bank, TBF Génie Tissulaire.

In this podcast episode, Ophthalmology Times' co-chief medical editors Peter J. McDonnell, MD, and Neda Shamie, MD, delve into the clinical nuances of Demodex blepharitis. Through personal anecdotes, they stress its underrecognized gravity and discuss diagnostic cues like collarettes. The experts share their enthusiasm for improved treatments, echoing the transformative impact seen in dry eye care.

Treating the meibomian glands and lifestyle changes are among some of the treatment methods.

Henriquez pointed out that waiting for keratoconic progression runs the inherent risk that keratoconus will progress rapidly and affect the planned initial treatment protocol.

Cultivated autologous limbal epithelial cells (CALEC) procedure shown to be safe and feasible with early positive results of restored cornea surfaces or vision gains in four patients with severe chemical burns.

According to the company, the primary endpoint for the NEXPEDE-1 study of lufepirsen ophthalmic gel will be complete corneal healing as determined by corneal fluorescein staining.

An area that attracts tourists and Christian pilgrims from around the world, has been found to contain microsporidium, which can cause corneal infections.

The trial will be an open-label trial in partnership with Tufts Medical Center. OK-101 is also being developed for use in dry eye disease.

This NDA transfer marks the fourth FDA-approved ophthalmic product purchased by Harrow earlier in 2023 now commercially available in the US.

With the potential to impact millions of patients, a study finds that biomimetic materials pulsed with low-energy blue light can reshape damaged corneas, including thickening the tissue.

Cedars-Sinai research is the first to uncover disease-related changes to the cornea and to propose potential therapeutic approaches to correct diabetic wound healing.

A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.

Severe ocular surface and corneal damage an unseen public health burden.

Surgeon discusses latest trends for treating cornea.

William B. Trattler, MD, highlights some of the novel therapies for dry eye that have recently been approved by the FDA, along with various treatment approaches that are in development.

Keratopigmentation technique offers therapeutic and cosmetic applications.

The company completed enrollment in less than 6 months from the trial commencement. The phase 3 trial results combined with the completion of the first phase 3 trial are expected to support the company’s targeted NDA submission for Epioxa by the end of 2024.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.

Groundbreaking treatment for patients with bullous keratopathy approved in Japan.

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

Zeba Syed, MD, from Wills Eye Hospital discussed their research on corneal swelling and dynamics during corneal collagen crosslinking at the 2023 ASCRS annual meeting in San Diego.

At the American Society of Cataract and Refractive Surgery annual meeting in San Diego, data was presented from the STORM study that demonstrate vision quality to be a major driver of the patient decision to undergo surgery.

Ophthalmology Times© spoke with Greg Kunst about Aurion BioTech's 12-month data from their recent Escalón trial 2023 at the ASCRS annual meeting in San Diego.